Top

Applied Health Economics and Health Policy

Published in:

01-01-2010 | Correspondence

The authors’ reply

Authors: George Dranitsaris, Sanjay Mehta

Published in: Applied Health Economics and Health Policy | Issue 1/2010

Excerpt

We would like to thank Lefebvre and Hunsche[1] for their interesting comments regarding our cost-minimization analysis (CMA) of four oral therapies for the treatment of pulmonary arterial hypertension (PAH).[2] The two main issues of debate are related to our assumption of clinical equivalence between drugs and the economic impact of secondary therapies that were used following adverse-effect-induced discontinuations of the initial agent. …

Lefebvre M-C, Hunsche E. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis [letter]. Appl Health Econ Health Policy 2010; 8(1): 69–71PubMed

Dranitsaris G, Mehta S. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis. Appl Health Econ Health Policy 2009; 7(1): 43–59PubMedCrossRef

Peacock AJ, Murphy NF, McMurray JJ, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007; 30: 104–9PubMedCrossRef

Song F, Altman DG, Glenny AM, et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003; 326: 472PubMedCrossRef

Barst R, Simin J, Gibbs R, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S78–84PubMedCrossRef

Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009; 30: 2493–537PubMedCrossRef

Rubin L, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896–903PubMedCrossRef

Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169: 441–7PubMedCrossRef

Kingman M, Ruggiero R, Torres F. Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 2009; 10: 1847–58PubMedCrossRef

10.

McGoon MD, Frost AE, Oudiz RJ, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 2009; 135: 122–9PubMedCrossRef

11.

Benza R, Mehta S, Keogh A, et al. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. J Heart Lung Transplant 2007; 26: 63–9PubMedCrossRef

Title: The authors’ reply
Authors: George Dranitsaris
Sanjay Mehta
Publication date: 01-01-2010
Publisher: Springer International Publishing
Published in: Applied Health Economics and Health Policy / Issue 1/2010
Print ISSN: 1175-5652
Electronic ISSN: 1179-1896
DOI: https://doi.org/10.1007/BF03256168

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The authors’ reply

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2010

Analytical strategies for characterizing chemotherapy diffusion with patient-level population-based data

Inpatient costs of endophthalmitis evaluated for the whole of France

Is the societal approach wide enough to include relatives?

Healthcare costs in renal transplant recipients using branded versus generic ciclosporin

Considering the value associated with innovation in health technology appraisal decisions (deliberations)

Ongoing pharmaceutical reforms in France